TY - JOUR
T1 - Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections
T2 - pooled data from phase 3 clinical trials
AU - Corey, Ralph
AU - Moran, Gregory
AU - Goering, Richard
AU - Bensaci, Mekki
AU - Sandison, Taylor
AU - De Anda, Carisa
AU - Prokocimer, Philippe
N1 - Funding Information:
Medical writing and/or editorial assistance was provided by Sally Mitchell, PhD, and Tracy Cao, PhD, of ApotheCom, Yardley, PA, USA, and Robert Schupp, PharmD, CMPP, of The Lockwood Group. This assistance was funded by MSD.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/7
Y1 - 2019/7
N2 - We evaluated the microbiological efficacy of tedizolid compared with that of linezolid against common and emerging pathogens using pooled data from 2 phase 3 trials (NCT01170221 and NCT01421511) in patients with acute bacterial skin and skin structure infections. Patients received tedizolid 200 mg once daily for 6 days (n = 664) or linezolid 600 mg twice daily for 10 days (n = 669). Favorable microbiological outcome in both treatment groups, defined as eradication or presumed eradication at the end of treatment and at the posttherapy evaluation, exceeded 85% for most pathogens, including methicillin-resistant Staphylococcus aureus. Favorable microbiological response was observed for staphylococci and streptococci at tedizolid minimal inhibitory concentration values ≤0.5 mg/L and 0.25 mg/L, respectively. The studies demonstrated positive microbiological outcomes against common pathogens with a 6-day, once-daily regimen of tedizolid phosphate in patients with acute bacterial skin and skin structure infections.
AB - We evaluated the microbiological efficacy of tedizolid compared with that of linezolid against common and emerging pathogens using pooled data from 2 phase 3 trials (NCT01170221 and NCT01421511) in patients with acute bacterial skin and skin structure infections. Patients received tedizolid 200 mg once daily for 6 days (n = 664) or linezolid 600 mg twice daily for 10 days (n = 669). Favorable microbiological outcome in both treatment groups, defined as eradication or presumed eradication at the end of treatment and at the posttherapy evaluation, exceeded 85% for most pathogens, including methicillin-resistant Staphylococcus aureus. Favorable microbiological response was observed for staphylococci and streptococci at tedizolid minimal inhibitory concentration values ≤0.5 mg/L and 0.25 mg/L, respectively. The studies demonstrated positive microbiological outcomes against common pathogens with a 6-day, once-daily regimen of tedizolid phosphate in patients with acute bacterial skin and skin structure infections.
UR - http://www.scopus.com/inward/record.url?scp=85063566389&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063566389&partnerID=8YFLogxK
U2 - 10.1016/j.diagmicrobio.2019.01.017
DO - 10.1016/j.diagmicrobio.2019.01.017
M3 - Article
C2 - 30940414
AN - SCOPUS:85063566389
VL - 94
SP - 277
EP - 286
JO - Diagnostic Microbiology and Infectious Disease
JF - Diagnostic Microbiology and Infectious Disease
SN - 0732-8893
IS - 3
ER -